Alzheimer's Disease

A biopharmaceutical company and the Miller School of Medicine at the University of Miami have announced a partnership to conduct a phase 1/2a clinical trial of ALZN002, a treatment for Alzheimer’s-related dementia.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.

People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.

A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting.

The Alzheimer’s Association is among a group of professional societies and research institutions that have launched the Alzheimer’s Network for Treatment and Diagnostics to collect data on patients treated with novel FDA-approved therapies.

Changes in gene expression patterns in the brain associated with natural aging also were observed in the brains of those with severe COVID-19, prompting researchers to emphasize the need for neurological follow-up in recovered individuals.

In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more.

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.